NCT05943977: A reported trial by Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
This trial has reported on time, in line with the regulations.
Full data
| Full entry on ClinicalTrials.gov | NCT05943977 |
|---|---|
| Title | A Randomized, Open Label, 2-Period, Cross-over Study to Evaluate the Bioequivalence of the Oversea Manufactured Sample and Domestic Manufactured Sample in Single Intravenous Dose of MB-102 (Relmapirazin) (Part I), and an Efficacy Study to Assess the Performance of the MediBeacon Transdermal GFR Measurement System and Domestic Manufactured Sample of MB-102 (Relmapirazin) for Evaluation of Kidney Function in Chinese Normal and Renal Compromised Subjects (Part II) |
| Results Status | Reported |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | March 2, 2023 |
| Completion date | Nov. 30, 2023 |
| Required reporting date | Nov. 29, 2024, midnight |
| Actual reporting date | Nov. 22, 2024 |
| Date last checked at ClinicalTrials.gov | Oct. 21, 2026 |
| Days late | None |